Atherosclerosis: Anti-inflammatory and immunomodulatory activities of statins

Autoimmunity Reviews

Volumn 2, Issue 6, 2003, Pages 332-338

  Kwak, Brenda R ^a   Mulhaupt, Flore ^a   Mach, François ^a  

^a UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Atherosclerosis; Cholesterol lowering; Immunomodulation; Inflammation; Statins

Indexed keywords

CD11 ANTIGEN; CD40 ANTIGEN; COLLAGEN; CYCLIN DEPENDENT KINASE INHIBITOR; DIMETHYLALLYLTRANSFERASE; FARNESYL DIPHOSPHATE; GAMMA INTERFERON; GELATINASE B; GUANINE NUCLEOTIDE BINDING PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IMMUNOSUPPRESSIVE AGENT; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERLEUKIN 8; LOW DENSITY LIPOPROTEIN RECEPTOR; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; MAJOR HISTOCOMPATIBILITY ANTIGEN CLASS 2; MEVALONIC ACID; MONOCYTE CHEMOTACTIC PROTEIN 1; NITRIC OXIDE; PADGEM PROTEIN; PROTEIN P27; RAS PROTEIN; RHO FACTOR; TRANSACTIVATOR PROTEIN; TUMOR NECROSIS FACTOR ALPHA;

ANTIGEN PRESENTING CELL; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ATHEROGENESIS; ATHEROSCLEROSIS; CELL CYCLE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL SYNTHESIS; CLINICAL TRIAL; COLLAGEN DEGRADATION; DENDRITIC CELL; DOWN REGULATION; EDEMA; ENDOTHELIUM CELL; ENDOTHELIUM INJURY; ENZYME INHIBITION; EXTRACELLULAR MATRIX; FLOW CYTOMETRY; FOOT PAD; GENE EXPRESSION; GRAFT REJECTION; HEART TRANSPLANTATION; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOMODULATION; INFLAMMATION; INFLAMMATORY CELL; ISOPRENYLATION; LEUKOCYTE; LIPID BLOOD LEVEL; MACROPHAGE; MONOCYTE; NONHUMAN; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN SECRETION; REVIEW; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; T LYMPHOCYTE;

EID: 0141750424     PISSN: 15689972     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1568-9972(03)00049-1     Document Type: Review

References (40)

1. Glass C.K., Witztum J.L. Atherosclerosis: the road ahead. Cell. 104:2001;503-516.
2. Ross R. Atherosclerosis: an inflammatory disease. N Engl J Med. 340:1999;115-126.
3. Libby P. Changing concepts of atherogenesis. J Intern Med. 247:2000;349-358.
4. Maron D.J., Fazio S., Linton M.F. Current perspectives on statins. Circulation. 101:2000;207-213.
5. Vaughan C.J., Gotto A.M., Basson C.T. The evolving role of statins in the management of atherosclerosis. J Am Coll Cardiol. 35:2000;1-10.
6. Takemoto M., Liao J.K. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol. 21:2001;1712-1719.
7. O'Driscoll G., Green D., Taylor R.R. Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month. Circulation. 95:1997;1126-1131.
8. Laufs U., La Fata V., Plutzky J., Liao J.K. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. Circulation. 97:1998;1129-1135.
9. Rikitake Y., Kawashima S., Takeshita S., Yamashita T., Azumi H., Yasuhara M., et al. Anti-oxidative properties of fluvastatin, an HMG-CoA reductase inhibitor, contribute to prevention of atherosclerosis in cholesterol-fed rabbits. Atherosclerosis. 154:2001;87-96.
10. Laufs U., Fata V.L., Liao J.K. Inhibition of 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase blocks hypoxia-mediated down-regulation of endothelial nitric oxide synthase. J Biol Chem. 272:1997;31725-31729.
11. Chen H., Ikeda U., Shimpo M., Shimada K. Direct effects of statins on cells primarily involved in atherosclerosis. Hypertens Res. 23:2000;187-192.
12. Ikeda U., Shimada K. Statins and monocytes. Lancet. 353:1999;2070.
13. Zelvyte I., Dominaitiene R., Crisby M., Janciauskiene S. Modulation of inflammatory mediators and pparα and nfκb expression by pravastatin in response to lipoproteins in human monocytes in vitro. Pharmacol Res. 45:2002;147-154.
14. Weber C., Erl W., Weber K.S., Weber P.C. HMG-CoA reductase inhibitors decrease CD11b expression and CD11b-dependent adhesion of monocytes to endothelium and reduce increased adhesiveness of monocytes isolated from patients with hypercholesterolemia. J Am Coll Cardiol. 30:1997;1212-1217.
15. Weitz-Schmidt G., Welzenbach K., Brinkmann V., Kamata T., Kallen J., Bruns C., et al. Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site. Nat Med. 7:2001;687-692.
16. Niwa S., Totsuka T., Hayashi S. Inhibitory effect of fluvastatin, an HMG-CoA reductase inhibitor, on the expression of adhesion molecules on human monocyte cell line. Int J Immunopharmacol. 18:1996;669-675.
17. Stalker T.J., Lefer A.M., Scalia R. A new HMG-CoA reductase inhibitor, rosuvastatin, exerts anti-inflammatory effects on the microvascular endothelium: the role of mevalonic acid. Br J Pharmacol. 133:2001;406-412.
18. Diomede L., Albani D., Sottocorno M., Donati M.B., Bianchi M., Fruscella P., et al. In vivo anti-inflammatory effect of statins is mediated by nonsterol mevalonate products. Arterioscler Thromb Vasc Biol. 21:2001;1327-1332.
19. Sparrow C.P., Burton C.A., Hernandez M., Mundt S., Hassing H., Patel S., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol. 21:2001;15-121.
20. Kobashigawa J.A., Katznelson S., Laks H., Johnson J.A., Yeatman L., Wang X.M., et al. Effect of pravastatin on outcomes after cardiac transplantation. N Engl J Med. 333:1995;621-627.
21. Wenke K., Meiser B., Thiery J., Nagel D., von Scheidt W., Steinbeck G., et al. Simvastatin reduces graft vessel disease and mortality after heart transplantation: a four-year randomized trial. Circulation. 96:1997;1398-1402.
22. Reith W., Mach B. The bare lymphocyte syndrome and the regulation of MHC expression. Annu Rev Immunol. 19:2001;331-373.
23. Muhlethaler-Mottet A., Otten L.A., Steimle V., Mach B. Expression of MHC class II molecules in different cellular and functional compartments is controlled by differential usage of multiple promoters of the transactivator CIITA. EMBO J. 16:1997;2851-2860.
24. Kwak B., Mulhaupt F., Myit S., Mach F. Statins as a newly recognized type of immunomodulator. Nat Med. 6:2000;1399-1402.
25. Kwak B., Mulhaupt F., Veillard N., Pelli G., Mach F. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells. Swiss Med Wkly. 131:2001;41-46.
26. Sadeghi M.M., Tiglio A., Sadigh K., O'Donnell L., Collinge M., Pardi R., et al. Inhibition of interferon-gamma-mediated microvascular endothelial cell major histocompatibility complex class II gene activation by HMG-CoA reductase inhibitors. Transplantation. 71:2001;1262-1268.
27. Raiteri M., Arnaboldi L., McGeady P., Gelb M.H., Verri D., Tagliabue C., et al. Pharmacological control of the mevalonate pathway: effect on arterial smooth muscle cell proliferation. J Pharmacol Exp Ther. 281:1997;1144-1153.
28. Soma M.R., Donetti E., Parolini C., Mazzini G., Ferrari C., Fumagalli R., et al. HMG CoA reductase inhibitors. In vivo effects on carotid intimal thickening in normocholesterolemic rabbits. Arterioscler Thromb. 13:1993;571-578.
29. Laufs U., Marra D., Node K., Liao J.K. 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors attenuate vascular smooth muscle proliferation by preventing Rho GTPase-induced downregulation of p27(Kip1). J Biol Chem. 274:1999;21 926-21 931.
30. Stark W.W. Jr, Blaskovich M.A., Johnson B.A., Qian Y., Vasudevan A., Pitt B., et al. Inhibiting geranylgeranylation blocks growth and promotes apoptosis in pulmonary vascular smooth muscle cells. Am J Physiol. 275:1998;L55-L63.
31. Guijarro C., Blanco-Colio L.M., Ortego M., Alonso C., Ortiz A., Plaza J.J., et al. 3-Hydroxy-3-methylglutaryl coenzyme a reductase and isoprenylation inhibitors induce apoptosis of vascular smooth muscle cells in culture. Circ Res. 83:1998;490-500.
32. Baetta R., Donetti E., Comparato C., Calore M., Rossi A., Teruzzi C., et al. Proapoptotic effect of atorvastatin on stimulated rabbit smooth muscle cells. Pharmacol Res. 36:1997;115-121.
33. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation. 104:2001;365-372.
34. Aikawa M., Rabkin E., Sugiyama S., Voglic S.J., Fukumoto Y., Furukawa Y., et al. An HMG-CoA reductase inhibitor, cerivastatin, suppresses growth of macrophages expressing matrix metalloproteinases and tissue factor in vivo and in vitro. Circulation. 103:2001;276-283.
35. Fukumoto Y., Libby P., Rabkin E., Hill C.C., Enomoto M., Hirouchi Y., et al. Statins alter smooth muscle cell accumulation and collagen content in established atheroma of watanabe heritable hyperlipidemic rabbits. Circulation. 103:2001;993-999.
36. Crisby M., Nordin-Fredriksson G., Shah P.K., Yano J., Zhu J., Nilsson J. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation. 103:2001;926-933.
37. Bellosta S., Via D., Canavesi M., Pfister P., Fumagalli R., Paoletti R., et al. HMG-CoA reductase inhibitors reduce MMP-9 secretion by macrophages. Arterioscler Thromb Vasc Biol. 18:1998;1671-1678.
38. Lijnen P., Echevaria-Vazquez D., Petrov V. Influence of cholesterol-lowering on plasma membrane lipids and function. Methods Find Exp Clin Pharmacol. 18:1996;123-136.
39. Schror K. Platelet reactivity and arachidonic acid metabolism in type II hyperlipoproteinaemia and its modification by cholesterol-lowering agents. Eicosanoids. 3:1990;67-73.
40. Bourcier T., Libby P. HMG CoA reductase inhibitors reduce plasminogen activator inhibitor-1 expression by human vascular smooth muscle and endothelial cells. Arterioscler Thromb Vasc Biol. 20:2000;556-562.